CLICK HERE FOR BRIUMVI® (ublituximab-xiiy) PRESCRIBING INFORMATION

FIERCELY FOCUSED
ON SCIENCE

OUR PIPELINE

REGIMEN Disease Preclinical Phase 1 Phase 2 Phase 3 Registration Status Learn More
Ublituximab: glycoengineered anti-CD20 mAb Relapsing MS
ULTIMATE I and II
APPROVED
12/28/2022
learnmore
Ublituximab: glycoengineered anti-CD20 mAb Relapsing MS
ENHANCE
learnmore
Azer-Cel: CD19 directed allogeneic CAR-T B-cell disorders
learnmore
TG-1801: anti-CD47/CD19 bispecific mAb B-cell disorders
learnmore
TG-1701: BTK inhibitor B-cell disorders
learnmore

The safety and efficacy of our investigational compounds and investigational uses of approved products have not been established. These products and uses have not been approved by the US Food and Drug Administration or other health authorities.

The safety and efficacy of our investigational compounds and investigational uses of approved products have not been established. These products and uses have not been approved by the US Food and Drug Administration or other health authorities.